Search Results

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia, announces the appointment of Sadia L’Baouch as Chief Manufacturing Officer, effective 4 January 2021.

Rexgenero announces that Dr Gilbert Wagener has joined the Company as Senior Vice President and Chief Medical Officer.

Rexgenero announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee.

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia, announces that Dr. David Horn Solomon has been appointed to the role of Chairman, effective immediately.

Rexgenero, a clinical-stage regenerative medicine company developing advanced cell-based therapies with a focus on Critical Limb Ischemia (CLI), today announces that its lead product REX-001 has been selected as one of only 14 products to be included in the EU Network for Health Technology Assessment (EUnetHTA) Prioritisation list (EPL) for Joint Assessment.

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.

Rexgenero is pleased to announce today the appointment of Sam MacHour to its SAB.

The project will focus on and design a cost effective commercial manufacturing strategy for Rexgenero’s novel autologous cell therapy REX-001.

REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients